Albert David Limited — Others, 04-07-2025: Shareholders meeting

Albert David Limited has announced a board meeting to consider the financial results for the quarter and half-year. The company reported revenue from operations of ₹345.77 Cr in FY 2025, compared to ₹362.46 Cr in FY 2024, with a profit before tax of ₹25.23 Cr against ₹97.29 Cr previously. Profit after tax stood at ₹17.20 Cr versus ₹75.42 Cr last year. The company has invested in expanding its field force and marketing, aiming for future growth despite near-term pressures. The Board has proposed a dividend of ₹5 per equity share of ₹10 each. Operationally, the company is strengthening specialty segment coverage and focusing on exports, institutions, and generics. The pharma market outlook remains positive with increasing demand and government support. The Board considered and recommended revisions in remuneration for the Executive Chairman and Managing Director & CEO for FY 2025-26. No significant litigations or compliance issues were reported, except some pending filings which the company is regularizing. Internal financial controls are deemed adequate and effective. The company continues CSR activities focused on health, education, environmental sustainability, and social welfare, spending ₹90.68 lakhs in FY 2025. The Board includes a mix of executive, non-executive, and independent directors, with recent appointments and resignations noted. The company maintains robust governance practices, including performance evaluations and adherence to regulatory requirements. Financial risk management policies address credit, liquidity, foreign exchange, interest rate, and market price risks with appropriate controls. Overall, Albert David is navigating the competitive pharmaceutical space with strategic investments and a stable financial position, aiming to grow shareholder value sustainably.